BECKMAN COULTER CARES SOLUTIONS
CARES SYSTEMS BRING HIV/AIDS MONITORING TO A HIGHER LEVEL OF AUTOMATION

SCIENCE SERVING HUMANITY
By focusing on innovative, yet affordable solutions for HIV monitoring, Beckman Coulter supports the UNAIDS 90-90-90 target to ensure that by the year 2020, 90% of people living with HIV will know their HIV status, 90% of people with diagnosed HIV infection will receive sustained antiretroviral therapy, and 90% of all people receiving antiretroviral therapy will have viral suppression.¹

To successfully optimize your laboratory, nothing is more important than choosing the right partner. When you select Beckman Coulter, you get a proactive collaborator to create innovative solutions for your everyday challenges. It’s a partnership that will provide the tools to improve the quality, workflow and operational efficiency of your laboratory, every step of the way.

Not all solutions are available in all countries. Please consult your local Beckman Coulter representative for details.

PUTTING THE POWER OF SCIENCE WHERE IT’S NEEDED MOST

Drawing from our history as leading biomedical life science companies, we’ve collaborated with healthcare leaders to develop breakthrough HIV monitoring solutions that contribute directly to the treatment process.

Your mission for timely HIV monitoring impacting treatment decisions in regions hardest hit by the disease, is what drives Beckman Coulter. At Beckman Coulter, we’re bringing a world of CARES to a world in need.
THE CARES INITIATIVE

The CARES initiative was launched and driven by a social and civic responsibility to support the fight against HIV/AIDS. Public and private partnerships are being explored to identify areas for Beckman Coulter to contribute for the broader purpose. We seek to develop alliances with non-governmental organizations (NGO’s), implementing partners, and health policy organizations to align our efforts.

Beckman Coulter is meeting tomorrow’s needs today by our commitment to leading the fight against HIV through the development of innovative solutions for the monitoring of CD4+ lymphocytes. Our simple, robust and sustainable tests have been made available to thousands of patients and allow the Health Departments to channel more funds towards better treatment programs.

References
1. 90-90-90: An ambitious treatment target to help end the AIDS epidemic - UNAIDS / JC2684 (English original, October 2014)
5. FLOW-H151WP0.15-A: Comparing the Aquios CL flow cytometer, the FACSScalibur flow cytometer, and the Unicel DxH800 hematology analyzer Tetra applications.
6. BR-31666: UniCel Dxi Access Immunoassay Systems
7. DS-51051: AU5800 Clinical Chemistry Systems

We are a global science & technology innovators committed to helping our customers solve complex challenges and improve quality of life worldwide. Our world class brands are leaders in some of the most demanding and attractive industries. A globally diverse team of 71,000 associates, we are united by our culture and operating system, the Danaher Business System, which is our competitive advantage.

The Life Science and Diagnostic segment consists of seven operating companies: Beckman Coulter Life Sciences, SCIEX, Leica Microsystems, Pall, Molecular Devices, Beckman Coulter Diagnostics, Leica Biosystems and Radiometer. We are global in reach, but local in service and support and in our collaborative approach to meeting your needs.